Medical Research
(H40)
990 on File
PROSTATE CANCER RESEARCH INC
Financial strength (30%)
35/100
Reliability (20%)
45/100
Effectiveness (25%)
58/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2023
$23K
Total Revenue
$421K
Total Expenses
$-722,622
Net Assets
3
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
57.1%
Fundraising Efficiency
N/A
Operating Reserve
-20.61x
Liability-to-Asset
2465.3%
Revenue Diversification
100.0%
Compared with Peers
FY 2023
Compared with 1,004 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2023.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
57.1% | 86.3% |
P10P90
|
Bottom quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
14.2% | 10.6% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
28.7% | 0.0% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
-20.6 mo | 13.1 mo |
P10P90
|
Bottom quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
2465.3% | 0.3% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
100.0% | 95.3% |
P10P90
|
Bottom quarter |
|
Expense growth
Year over year expense growth
|
43.2% | 12.9% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-1754.5% | -0.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2023 | $23K | $421K | $-722,622 | 57.1% | 3 |
| 2022 | $0 | $294K | $-324,984 | 7.0% | 2 |
| 2021 | $66K | $179K | N/A | — | 2 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.